

SPECIALTY QUANTITY LIMIT PROGRAM

HUMAN IMMUNODEFICIENCY VIRUS (HIV) MEDICATIONS

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit*	FDA-recommended dosing
Aptivus (tipranavir) capsules 250 mg	120 per 30 days	<ul style="list-style-type: none"> • Adults: 500 mg with ritonavir twice daily • Pediatric patients: Based on body weight or body surface area not to exceed adult dose
Aptivus (tipranavir) oral solution 100 mg/mL	285 mL per 28 days	
Atripla (efavirenz 600 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Biktarvy (bictegravir 50mg, emtricitabine 200mg, and tenofovir alafenamide 25mg) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Cimduo (lamivudine 300mg and tenofovir disoproxil fumarate 300mg) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Combivir (lamivudine 150 mg and zidovudine 300 mg) tablets	60 per 30 days	<ul style="list-style-type: none"> • Adults and adolescents weighing \geq 30 kg: one tablet twice daily • Pediatric patients: Based on body weight not to exceed adult doses
Complera (emtricitabine 200 mg, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Crixivan (indinavir sulfate) capsules 200 mg	450 per 30 days	<ul style="list-style-type: none"> • 800 mg three times daily • 600 mg three times daily when administering <ul style="list-style-type: none"> - delavirdine 400 mg three times a day - itraconazole 200 mg twice daily concurrently or - ketoconazole concurrently - mild-to-moderate hepatic insufficiency due to cirrhosis • 1000 mg three times daily when co-administered with rifabutin
Crixivan (indinavir sulfate) capsules 400 mg	180 per 30 days	

Reference number(s)
1804-H

Medication	Standard Limit*	FDA-recommended dosing
Delstrigo (doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300mg) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily • Co-administration with rifabutin: one tablet of Delstrigo once daily followed by one tablet of Pifeltro approximately 12 hours after the dose of Delstrigo
Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Dovato (dolutegravir 50mg and lamivudine 300mg) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Edurant (rilpivirine) tablets 25 mg	60 per 30 days	<ul style="list-style-type: none"> • One tablet once daily • Two tablets once daily when co-administered with rifabutin
Emtriva (emtricitabine) capsules 200 mg	30 per 30 days	<ul style="list-style-type: none"> • Adult patients: one capsule once daily • Pediatric patients: one capsule once daily
Emtriva (emtricitabine) oral solution 10 mg/mL	680 mL per 28 days	<ul style="list-style-type: none"> • Adult patients: 240 mg (24 mL) once daily • Pediatric patients aged 3 months to 17 years: 6 mg/kg up to a maximum of 240 mg (24 mL) once daily • Pediatric patients aged 0 to 3 months: 3 mg/kg once daily
Epivir (lamivudine) oral solution 10 mg/mL	900 mL per 30 days	<ul style="list-style-type: none"> • Adults and adolescents > 16 years of age: 150 mg twice daily or 300 mg once daily • Pediatric patients aged 3 months to 16 years: 4 mg/kg twice daily (up to a maximum of 150 mg twice a day)
Epivir (lamivudine) tablets 150 mg	60 per 30 days	
Epivir (lamivudine) tablets 300 mg	30 per 30 days	
Epzicom (abacavir 600 mg and lamivudine 300 mg) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Fuzeon (enfuvirtide) inj 90 mg vial	60 per 30 days	<ul style="list-style-type: none"> • Adults: 90 mg twice daily • Pediatric patients (6 to 16 years of age): 2 mg/kg twice daily, not to exceed the adult dose
Genvoya (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) tablets	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Intelence (etravirine) tablets 25 mg	120 per 30 days	<ul style="list-style-type: none"> • Adult patients: 200 mg twice daily • Pediatric patients (≥ 2 years and weighing at least 10 kg): 100 mg, 125 mg, 150 mg, or 200 mg, based on body weight
Intelence (etravirine) tablets 100 mg	120 per 30 days	
Intelence (etravirine) tablets 200 mg	60 per 30 days	
Invirase (saquinavir mesylate) capsules 200 mg	300 per 30 days	<ul style="list-style-type: none"> • 1000 mg twice daily

Reference number(s)
1804-H

Medication	Standard Limit*	FDA-recommended dosing
Invirase (saquinavir mesylate) tablets 500 mg	120 per 30 days	
Isentress (raltegravir) chewable tablets 25 mg	180 per 30 days	<ul style="list-style-type: none"> • Adult patients: 400 mg twice daily; 800 mg twice daily when coadministered with rifampin • Children and adolescents: 25-400 mg twice daily, based on body weight • Neonates: up to 15mg twice daily, based on body weight
Isentress (raltegravir) powder 100 mg packet	60 per 30 days	
Isentress (raltegravir) chewable tablets 100 mg	180 per 30 days	
Isentress (raltegravir) tablets 400 mg	120 per 30 days	
Isentress (raltegravir) HD tablets 600 mg	60 per 30 days	<ul style="list-style-type: none"> • 1200 mg (two 600 mg tablets) film-coated tablet orally, once daily
Juluca (dolutegravir-rilpivirine) tablets 50-25 mg	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily
Kaletra (lopinavir 80 mg/ritonavir 20 mg per mL) sol	390 per 30 days	<ul style="list-style-type: none"> • Adults: 800 mg/200 mg (in tablets or oral solution) given once daily or 400 mg/100 mg twice daily; 500 mg/125 mg (2 tablets of 200 mg/50 mg + 1 tablet of 100 mg/25 mg) twice daily or 520 mg/130 mg (6.5 mL of oral solution) twice daily when co-administered with efavirenz, nevirapine, or nelfinavir • Pediatric patients: Based on body weight and body surface area, up to a maximum dose of 400 mg/100 mg twice daily
Kaletra (lopinavir-ritonavir) tablets 100-25 mg	240 per 30 days	
Kaletra (lopinavir-ritonavir) tablets 200-50 mg	120 per 30 days	
Lexiva (fosamprenavir) suspension 50 mg/mL	1575 mL per 28 days	<ul style="list-style-type: none"> • Adults: 1400 mg twice daily, 1400 mg once daily with ritonavir, or 700 mg twice daily with ritonavir; 350-700 mg twice daily without ritonavir (therapy-naive) or 300-450 mg twice daily plus ritonavir once daily with moderate to severe hepatic impairment • Pediatric patients: Based on body weight (18 to 45 mg per kg), up to a maximum dose of 400 mg/100 mg twice daily
Lexiva (fosamprenavir) tablets 700 mg	120 per 30 days	
Norvir (ritonavir) capsules 100 mg	360 per 30 days	<ul style="list-style-type: none"> • Adults: 600 mg twice daily • Pediatric patients: Based on body surface area, up to a maximum dose of 600 mg twice daily
Norvir (ritonavir) oral solution 80 mg/mL	480 mL per 30 days	
Norvir (ritonavir) tablets 100 mg	360 per 30 days	
Norvir (ritonavir) oral powder, 100mg packet (30 per carton)	360 packets per 30 days	
Odefsey (emtricitabine 200 mg, rilpivirine 25 mg, tenofovir alafenamide 25 mg) tab	30 per 30 days	<ul style="list-style-type: none"> • One tablet once daily

Medication	Standard Limit*	FDA-recommended dosing
Pifeltro (doravirine) tablets 100 mg	60 per 30 days	<ul style="list-style-type: none"> One tablet once daily Co-administration with rifabutin: one tablet twice daily
Prezcobix (darunavir 800 mg and cobicistat 150 mg) tablets	30 per 30 days	<ul style="list-style-type: none"> One tablet once daily
Prezista (darunavir) tablets 150 mg	180 per 30 days	<ul style="list-style-type: none"> Adults with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet or 8 mL of oral suspension) with ritonavir Pregnancy or adults with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet or 6 mL of oral suspension) with ritonavir twice daily Pediatric patients: Based on body weight, not to exceed the adult dose
Prezista (darunavir) tablets 75 mg	300 per 30 days	
Prezista (darunavir) suspension 100 mg/mL	400 mL per 30 days	
Prezista (darunavir) tablets 600 mg	60 per 30 days	
Prezista (darunavir) tablets 800 mg	30 per 30 days	
Rescriptor (delavirdine mesylate) tablets 100 mg	900 per 30 days	<ul style="list-style-type: none"> 400 mg three times daily 1000 mg three times daily with rifabutin co-administration
Rescriptor (delavirdine mesylate) tablets 200 mg	450 per 30 days	
Retrovir (zidovudine) capsules 100 mg	180 per 30 days	<ul style="list-style-type: none"> Adults: 300 mg twice daily; 100 mg every 6 to 8 hours with renal impairment Pediatric patients: Based on body weight, not to exceed the adult dose
Retrovir (zidovudine) syrup 10 mg/mL	1800 mL per 30 days	
Retrovir (zidovudine) tablets 300 mg	60 per 30 days	
Reyataz (atazanavir) capsules 150 mg	30 per 30 days	<ul style="list-style-type: none"> Adults: 300 mg with ritonavir once daily or 400 mg once daily Pediatric patients: Based on body weight, not to exceed the adult dose
Reyataz (atazanavir) capsules 200 mg	60 per 30 days	
Reyataz (atazanavir) capsules 300 mg	30 per 30 days	
Reyataz (atazanavir) powder 50 mg packet	180 packets per 30 days	
Selzentry (maraviroc) tablets 25 mg	240 per 30 days	<ul style="list-style-type: none"> Adults: 150 mg, 300 mg or 600 mg twice daily, depending on co-administered medications Pediatric patients: 50 mg, 75 mg, 100 mg, 150 mg or 300 mg twice daily, depending on body weight and co-administered medications
Selzentry (maraviroc) tablets 75 mg	60 per 30 days	
Selzentry (maraviroc) tablets 150 mg	60 per 30 days	
Selzentry (maraviroc) tablets 300 mg	120 per 30 days	
Selzentry (maraviroc) oral solution 20 mg/mL	1840 mL per 30 days	
Stribild (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg) tablets	30 per 30 days	<ul style="list-style-type: none"> One tablet once daily

Reference number(s)
1804-H

Medication	Standard Limit*	FDA-recommended dosing
Sustiva (efavirenz) capsules 50 mg	90 per 30 days	<ul style="list-style-type: none"> Adults: 600 mg once daily; 800 mg once daily when co-administered with rifampin Pediatric patients: 100-600 mg based on body weight
Sustiva (efavirenz) capsules 200 mg	90 per 30 days	
Sustiva (efavirenz) tablets 600mg	30 per 30 days	
Symfi (efavirenz 600mg, lamivudine 300mg and tenofovir disoproxil fumarate 300mg) tablets	30 per 30 days	<ul style="list-style-type: none"> One tablet once daily
Symfi Lo (efavirenz 400mg, lamivudine 300mg and tenofovir disoproxil fumarate 300mg) tablets	30 per 30 days	<ul style="list-style-type: none"> One tablet once daily
Symtuza (darunavir 800mg, cobicistat 150mg, emtricitabine 200mg, tenofovir alafenamide 10mg)	30 per 30 days	<ul style="list-style-type: none"> One tablet once daily
Temixys (lamivudine 300mg, tenofovir disoproxil fumarate 300mg)	30 per 30 days	<ul style="list-style-type: none"> One tablet once daily
Tivicay (dolutegravir) tablets 10 mg	60 per 30 days	<ul style="list-style-type: none"> Adults: 50 mg once daily; 50 mg twice daily with certain CYP3A inducers or uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) Pediatric patients weighing \geq 30 kg: 35 mg or 50 mg once daily, based on body weight. 35 mg or 50 mg twice daily, based on body weight when co-administered with certain CYP3A inducers or uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1)
Tivicay (dolutegravir) tablets 25 mg	60 per 30 days	
Tivicay (dolutegravir) tablets 50 mg	60 per 30 days	
Triumeq (abacavir 600 mg, dolutegravir 50 mg, lamivudine 300 mg) tablets	30 per 30 days	<ul style="list-style-type: none"> One tablet once daily
Trizivir (abacavir 300 mg, lamivudine 150 mg, and zidovudine 300 mg) tablets	60 per 30 days	<ul style="list-style-type: none"> One tablet twice daily
Truvada (emtricitabine and tenofovir disoproxil fumarate) tablets 100-150	30 per 30 days	<ul style="list-style-type: none"> One tablet once daily One tablet every 48 hours with renal impairment
Truvada (emtricitabine and tenofovir disoproxil fumarate) tablets 133-200	30 per 30 days	
Truvada (emtricitabine and tenofovir disoproxil fumarate) tablets 167-250	30 per 30 days	
Truvada (emtricitabine and tenofovir disoproxil fumarate) tablets 200-300	30 per 30 days	
Tybost (cobicistat) tablets 150mg	30 per 30 days	<ul style="list-style-type: none"> One tablet once daily

Reference number(s)
1804-H

Medication	Standard Limit*	FDA-recommended dosing
Videx (didanosine) EC capsules 125 mg	30 per 30 days	<ul style="list-style-type: none"> • One capsule (125 mg, 200 mg, 250 mg, or 400 mg based on body weight and creatinine clearance) once daily
Videx (didanosine) EC capsules 200 mg	30 per 30 days	
Videx (didanosine) EC capsules 250 mg	30 per 30 days	
Videx (didanosine) EC capsules 400 mg	30 per 30 days	
Videx (didanosine) Solution 2 g/ 4 oz.	1200 mL per 30 days	<ul style="list-style-type: none"> • Adults: 125 mg (< 60 kg) or 200 mg (≥ 60 kg) twice daily or 250 mg (< 60 kg) or 400 mg (≥ 60 kg) once daily • Pediatric patients: 100 mg/m² (2 weeks to 8 months old) or 120 mg/m² (> 8 months old) twice daily
Videx (didanosine) Solution 4 g/ 8 oz.	1200 mL per 30 days	
Viracept (nelfinavir) tablets 250 mg	300 per 30 days	<ul style="list-style-type: none"> • Adults and adolescents: 1250 mg twice daily or 750 mg three times daily • Pediatric patients < 13 years of age: 45 to 55 mg/kg twice daily or 25-35 mg/kg three times daily, up to a maximum of five 250-mg tablets twice daily or three 250-mg tablets three times daily
Viracept (nelfinavir) tablets 625 mg	120 per 30 days	
Viramune (nevirapine) suspension 50 mg/5 mL	1200 mL per 30 days	<ul style="list-style-type: none"> • Adults: 200 mg once daily for 14 days and then 200 mg twice daily • Pediatric patients: 150 mg/m² once daily for 14 days and then 150 mg/m² twice daily, not to exceed a total daily dose 400 mg
Viramune (nevirapine) tablets 200 mg	60 per 30 days	
Viramune (nevirapine) XR tablets 100 mg	90 per 30 days	
Viramune (nevirapine) XR tablets 400 mg	30 per 30 days	<ul style="list-style-type: none"> • Adults: One 400 mg tablet once daily • Pediatric patients ≥ 6 years of age: 200 mg, 300 mg, or 400 mg once daily
Viread (tenofovir disoproxil fumarate) powder 40 mg/g	240 g per 30 days	
Viread (tenofovir disoproxil fumarate) tablets 150 mg	30 per 30 days	
Viread (tenofovir disoproxil fumarate) tablets 200 mg	30 per 30 days	
Viread (tenofovir disoproxil fumarate) tablets 250 mg	30 per 30 days	
Viread (tenofovir disoproxil fumarate) tablets 300 mg	30 per 30 days	
Zerit (stavudine) capsules 15 mg	60 per 30 days	<ul style="list-style-type: none"> • Adults: 15 mg, 20 mg, 30 mg or 40 mg twice daily or 15 mg or 20 mg once daily (based on body weight and creatinine clearance) • Pediatric patients: Based on body weight and age, not to exceed the adult dose
Zerit (stavudine) capsules 20 mg	60 per 30 days	
Zerit (stavudine) capsules 30 mg	60 per 30 days	
Zerit (stavudine) capsules 40 mg	60 per 30 days	
Zerit (stavudine) oral solution 1 mg/mL	2400 mL per 30 days	

Reference number(s)
1804-H

Medication	Standard Limit*	FDA-recommended dosing
Ziagen (abacavir) oral solution 20 mg/mL	900 mL per 30 days	<ul style="list-style-type: none"> Adults: 600 mg daily, administered as either 300 mg twice daily or 600 mg once daily; 200 mg twice daily with hepatic impairment Pediatric patients: Based on body weight, not to exceed the adult dose
Ziagen (abacavir) tablets 300 mg	60 per 30 days	

*The initial limits may apply to the generic equivalent medications.

III. REFERENCES

1. Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 2018.
2. Atripla [package insert]. New York, NY: Bristol Myers Squibb; July 2018.
3. Biktarvy [package insert]. Foster City, CA: Gilead Sciences, Inc.; February 2018.
4. Cimduo [package insert]. Morgantown, WV: Mylan Specialty, L.P.; February 2018.
5. Combivir [package insert]. Research Triangle Park, NC: ViiV Healthcare; April 2018.
6. Complera [package insert]. Foster City, CA: Gilead Sciences, Inc.; October 2018.
7. Crixivan [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; September 2016.
8. Delstrigo [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; August 2018.
9. Descovy [package insert]. Foster City, CA: Gilead Sciences, Inc.; September 2017.
10. Dovato [package insert]. Research Triangle Park, NC: ViiV Healthcare; April 2019.
11. Edurant [package insert]. Foster City, CA: Gilead Sciences, Inc.; February 2018.
12. Emtriva [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2017.
13. Epivir [package insert]. Research Triangle Park, NC: ViiV Healthcare; April 2018.
14. Epzicom [package insert]. Research Triangle Park, NC: ViiV Healthcare; April 2018.
15. Evotaz [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; March 2018.
16. Fuzeon [package insert]. South San Francisco, CA: Genentech USA, Inc.; December 2016.
17. Genvoya [package insert]. Foster City, CA: Gilead Sciences, Inc.; December 2018.
18. Intelence [package insert]. Titusville, NJ: Janssen Therapeutics; November 2018.
19. Invirase [package insert]. South San Francisco, CA: Genentech USA, Inc.; March 2018.
20. Isentress [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; March 2018.
21. Juluca [package insert]. Research Triangle Park, NC: ViiV Healthcare; September 2018.
22. Kaletra [package insert]. North Chicago, IL: AbbVie, Inc.; November 2018.
23. Lexiva [package insert]. Research Triangle Park, NC: ViiV Healthcare; December 2017.
24. Norvir tablets and oral solution [package insert]. North Chicago, IL: AbbVie, Inc.; November 2018.
25. Norvir capsules [package insert]. North Chicago, IL: AbbVie, Inc.; November 2018.
26. Odefsey [package insert]. Foster City, CA: Gilead Sciences, Inc.; October 2018.
27. Pifeltro [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; August 2018.
28. Prezcoibix [package insert]. Titusville, NJ: Janssen Therapeutics; September 2018.
29. Prezista [package insert]. Titusville, NJ: Janssen Therapeutics; January 2018.
30. Rescriptor [package insert]. Research Triangle Park, NC: ViiV Healthcare; March 2018.
31. Retrovir [package insert]. Research Triangle Park, NC: ViiV Healthcare; September 2018.
32. Reyataz [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; March 2018.
33. Selzentry [package insert]. Research Triangle Park, NC: ViiV Healthcare; July 2018.
34. Stribild [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2018.
35. Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; October 2017.
36. Symfi [package insert]. Morgantown, WV: Mylan Specialty, L.P.; March 2018.
37. Symfi Lo [package insert]. Morgantown, WV: Mylan Specialty, L.P.; February 2018.
38. Symtuza [package insert]. Titusville, NJ: Janssen Therapeutics; July 2018.
39. Temixys [package insert]. Republic of Korea: Celltrion Pharm, Inc.; November 2018.

Reference number(s)
1804-H

40. Tivicay [package insert]. Research Triangle Park, NC: ViiV Healthcare; September 2018.
41. Triumeq [package insert]. Research Triangle Park, NC: ViiV Healthcare; September 2018.
42. Trizivir [package insert]. Research Triangle Park, NC: ViiV Healthcare; April 2018.
43. Truvada [package insert]. Foster City, CA: Gilead Sciences, Inc.; May 2018.
44. Tybost [package insert]. Foster City, CA: Gilead Sciences, Inc.; October 2018.
45. Videx EC [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; January 2018.
46. Videx pediatric powder [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; December 2018.
47. Viracept [package insert]. Research Triangle Park, NC: ViiV Healthcare; September 2016.
48. Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; September 2018.
49. Viramune XR [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; September 2018.
50. Viread [package insert]. Foster City, CA: Gilead Sciences, Inc.; July 2018.
51. Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; December 2018.
52. Ziagen [package insert]. Research Triangle Park, NC: ViiV Healthcare; May 2018.